Autografting in chronic myeloid leukemia

Seminars in Hematology

Volumn 40, Issue 1, 2003, Pages 72-78

  Carella, Angelo M ^a   Beltrami, Germana ^a   Corsetti, Maria T ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HLA ANTIGEN; IMATINIB;

ADULT; ALLOGRAFT; AUTOGRAFT; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; HUMAN; LEUKEMIA REMISSION; PATIENT MOBILITY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0037258489     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(03)70044-4     Document Type: Review

References (40)

1. Bergamaschi G, Podestà M, Frassoni F, et al: Restoration of normal polyclonal hemopoiesis in patients with chronic myeloid leukemia autografted with Phi-negative peripheral stem cells. Br J Haematol 87:867-870, 1994
2. Breems DA, van Hennik PB, Kusadasi N, et al: Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells. Blood 87:5370-5378, 1996
3. Carella AM, Cunningham I, Lerma E, et al: Mobilization and transplantation of Philadelphia-negative peripheral blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol 15:1575-1582, 1997
4. Carella AM, Dejana A, Lerma E, et al: In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukaemia. Br J Haematol 95:127-130, 1996
5. Carella AM, Frassoni F, Pollicardo N et al: Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukemia. Br J Haematol 89:535-538, 1995
6. Carella AM, Lerma E, Corsetti MT, et al: Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 93:1534-1539, 1999
7. Carella AM, Simonsson B, Link H, et al: Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha. Br J Haematol 101:111-118, 1998
8. Chalmers EA, Franklin IM, Kelsey SM, et al: Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: Mobilization of Philadelphia-negative peripheral blood stem cells. Br J Haematol 96:627-634, 1997
9. Corsetti MT, Lerma E, Dejana A, et al: Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft. Exp Hematol 28:104-111, 2000
10. Coulombel L, Kalousek DK, Eaves CJ, et al: Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukaemia. N Engl J Med 308:1493-1498, 1983
11. Cross NCP, Feng L, Chase A, et al: Competitive polymerase chain reaction to estimate the number of BCR/ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1926-1936, 1993
12. Druker BJ, Talpaz M, Resta R, et al: Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as target therapy for chronic myelogenous leukemia. Blood 94:368a, 1999 (suppl 1, abstr)
13. Druker BJ, Tamura S, Buchdunger E, et al: Effect of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 2:561-566, 1996
14. Dube ID, Arlin ZA, Kalousek DK, et al: Non-clonal hematopoietic progenitor cells detected in long-term marrow cultures from a Turner syndrome mosaic with chronic myeloid leukemia. Blood 64:1284-1287, 1984
15. Fisher T, Neubauer A, Mohm J, et al: Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied. Ann Hematol 77:21-26, 1998
16. Goldman J: The decision whether to allograft a patient with CML, in Carella AM, Daley GQ, Eaves CJ, et al (eds): Chronic Myeloid Leukaemia: Biology and Treatment. London, UK, Martin Dunitz, 2002, pp 263-271
17. Goto T, Nishikori M, Arlin Z, et al: Growth characteristics of leukemic and normal hematopoietic cells in Ph+ chronic myelogenous leukemia and effects of intensive treatment. Blood 59:793-808, 1982
18. Heinzinger M, Waller CF, Rosenstiel A, et al: Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML. Leukemia 12:333-339, 1998
19. Ho AD, Young D, Maruyama M, et al: Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both. Exp Hematol 24:1460-1468, 1996
20. Hochhaus A, Reiter A, Saussele S, et al: Molecular heterogeneity in complete cytogenetic responders after Interferon-α therapy for chronic myeloid leukemia: Low levels of minimal residual disease are associated with continuing remission. Blood 95:62-66, 2000
21. Hogge DE, Coulombel L, Kalousek DK, et al: Non-clonal hematopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. Am J Hematol 24:389-394, 1987
22. Holyoake T, Jiang X, Eaves C, et al: Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94:2056-2064, 1999
23. Johnson RJ, Owen RG, Child JA, et al: Mobilization of Philadelphia-negative peripheral blood mononuclear cells in chronic myeloid leukaemia using hydroxyurea and G-CSF (filgrastim). Br J Haematol 93:863-868, 1996
24. Kantarjian HM, Cortes J, O'Brien S, et al: Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99:3547-3553, 2002
25. Kantarjian HM, Talpaz M, Hester J, et al: Collection of peripheral blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive chemotherapy. J Clin Oncol 13:553-559, 1995
26. Kantarjian HM, Vellekoop L, McCredie KB, et al: Intensive combination chemotherapy (ROAP 10) and splenectomy in management of chronic myelogenous leukemia. J Clin Oncol 3:192-200, 1985
27. Lennard A, Storey N, Dickinson AM, et al: Collection of Philadelphia-negative peripheral blood progenitor cells in unselected patients with chronic granulocytic leukaemia. Northern Regional Haematology Group. Leukemia 12:746-752, 1998
28. Morton J, Mollee P, Taylor K, et al: Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. Leuk Res 23:177-183, 1999
29. Podestà M, Piaggio G, Frassoni F, et al: Very primitive hemopoietic cells (LTC-IC) are present in Philadelphia negative cytaphereses collected during early recovery after chemotherapy for chronic myelogenous leukemia. Bone Marrow Transplant 16:549-555, 1995
30. Prosper F, Stroneck D, Verfaillie CM: Phenotypic and functional characterization of long-term culture-initiating cells in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor. Blood 88:2033-2042, 1996
31. Sureda A, Petit J, Brunet S, et al: Mini-ICE regimen as mobilization therapy for chronic myelogenous leukaemia patients at diagnosis. Bone Marrow Transplant 12:1285-1290, 1999
32. Sutherland HJ, Eaves CJ, Eaves AC, et al: Characterization and partial purification of human marrow cells capable of initiating long-term hematopiesis in vitro. Blood 74:1563-1570, 1989
33. Talpaz M, Kantarjian H, Kurzrock R, et al: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia Philadelphia chromosome-positive patients. Ann Intern Med 114:532-538, 1991
34. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99:1928-1937, 2002
35. Turhan AG, Humphries RK, Eaves CJ, et al: Detection of breakpoint cluster region-negative and nonclonal hematopoiesis in vitro and in vivo after transplantation of cells selected in cultures of chronic myeloid leukemia marrow. Blood 76:2404-2410, 1990
36. Van den Berg D, Wessman M, Murray L, et al: Leukemic burden in subpopulations of CD34+ cells isolated from the mobilised peripheral blood of alfa-interferon-resistant or intolerant patients with chronic myeloid leukemia. Blood 87:4348-4357, 1996
37. Verfaillie CM, Bhatia R, Steinbuch M, et al: Comparative analysis of autografting in chronic myelogenous leukemia: Effects of priming regimen and marrow or blood origin of stem cells. Blood 92:1820-1831, 1998
38. Waller CF, Heinzinger M, Rosenstiel A, et al: Mobilization and transplantation of Philadelphia chromosome-negative peripheral blood progenitor cells in patients with CML. Br J Haematol 103:227-234, 1998
39. Wang JCY, Lapidot T, Cashman JD, et al: High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukaemia in chronic phase. Blood 91:2406-2414, 1998
40. Weaver A, Ryder D, Crowther D, et al: Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administrated in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. Blood 88:3323-3328, 1996